Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis

[1] Patel AP(2019)Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 376-393

[2] Fisher JL(2018)Epidemiology of gynecologic cancers in China J Gynecol Oncol 29 e7-202

[3] Nichols E(2015)Breast cancer risk factors Przeglad Menopauzalny = Menopause Rev 14 196-106

[4] Abd-Allah F(2018)Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis Genes Dis 5 77-524

[5] Abdela J(2020)Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR J Oncol 2020 9258396-401

[6] Abdelalim A(2016)PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment Cancer Metastasis Rev 35 515-7735

[7] Abraha HN(2018)Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer Breast Cancer 25 392-13

[8] Agius D(2005)Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721-1283

[9] Alahdab F(2001)Biology of HER2 and its importance in breast cancer Oncology 61 1-1004

[10] Alam T(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-5172

[1] Patel AP(2019)Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 376-393

[2] Fisher JL(2018)Epidemiology of gynecologic cancers in China J Gynecol Oncol 29 e7-202

[3] Nichols E(2015)Breast cancer risk factors Przeglad Menopauzalny = Menopause Rev 14 196-106

[4] Abd-Allah F(2018)Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis Genes Dis 5 77-524

[5] Abdela J(2020)Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR J Oncol 2020 9258396-401

[6] Abdelalim A(2016)PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment Cancer Metastasis Rev 35 515-7735

[7] Abraha HN(2018)Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer Breast Cancer 25 392-13

[8] Agius D(2005)Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721-1283

[9] Alahdab F(2001)Biology of HER2 and its importance in breast cancer Oncology 61 1-1004

[10] Alam T(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-5172